TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06668194

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Force (150g Niti Coil)
Description: Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (150g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heavy Force (400 g Niti coil)
Description: Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (400g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms
Study: NCT06668649

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing with Questionnaires
Description: Testing with following Questionnaires: pFSS, Polish-language version of Modified Fatigue Impact Scale, Visual Analogue Scale of Fatigue, EQ-5D-5L (EuroQol-5 dimension) questionnaire, Beck Depression Inventory II. In randomly selected 30 patients and 20 controls questionnaires will be administered twice with two weeks interval to assess the test-retest reliability.

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing with Questionnaires
Description: Testing with following Questionnaires: pFSS, Polish-language version of Modified Fatigue Impact Scale, Visual Analogue Scale of Fatigue, EQ-5D-5L (EuroQol-5 dimension) questionnaire, Beck Depression Inventory II. In randomly selected 30 patients and 20 controls questionnaires will be administered twice with two weeks interval to assess the test-retest reliability.
Study: NCT04635059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
Study: NCT06680778

Intervention type: DEVICE
Intervention: Proactive Monitoring
Description: Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit
Study: NCT06680583

Intervention type: OTHER
Intervention: physical indicators such as shock index relatives
Description: shock index relatives indicators used in the prediction of cirrhosis with gastrointestinal bleeding
Study: NCT06680219

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Crystal Light Raspberry Lemonade: Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily (8-12 oz of water is approximately 236-354 mL of water).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: ACTIVE - Nu Biome (Formula #: 95001996; Batch #: EV24931): Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily.~(8-12 oz of water is approximately 236-354 mL of water).
Study: NCT06680752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARD103
Description: ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: iv administration for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: iv administration for lymphodepletion
Study: NCT06680466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729
Description: Dose Group 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: morphine,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729
Description: Dose Group 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729
Description: Dose Group 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729
Description: Dose Group 4
Study: NCT06344455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Retention and Completion Incentive Savings via Modified Iowa Gambling Task A
Description: Participants will engage in a modified version of the Iowa Gambling Task with visual stimuli that are aligned with the Pé-de-Meia program's requirements. Advantageous cards will display images that are congruent with the program's criteria, while disadvantageous cards will feature images that are contrary to the Pé-de-Meia program's requirements.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Iowa Gambling Task
Description: The participants will play the unmodified Iowa Gambling Task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Retention and Completion Incentive Savings via Modified Iowa Gambling Task B
Description: The participants will play the modified IGT (Iowa Gambling Task). For the disadvantageous cards, images that align with the requirements of the Pé-de-Meia program will be presented, while for the advantageous cards, images that contradict the criteria of the Pé-de-Meia program will be shown.
Study: NCT05380531

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative Genotyping
Description: Genotype based risk prediction and personalized pain management
Study: NCT06681441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Study: NCT06681441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Study: NCT06676488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Re-Timer glasses
Description: Morning bright light therapy (BLT) will be administered through a safe wearable glasses device called a Re-Timer, purchased from the manufacturer Re-Timer.
Study: NCT05951166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gradient Denervation System
Description: Pulmonary artery denervation (PADN) procedure
Study: NCT06676488

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: Placebo glasses not providing Bright Light Therapy
Study: NCT06681402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLAMOD
Description: FLAMOD (GMP-grade flagellin) inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation
Study: NCT06680180

Intervention type: DIAGNOSTIC_TEST
Intervention: Viscoelastometric assessment of fibrinolysis
Description: Viscoelastometric assessment of whole blood fibrinolysis using supplemental tissue plasminogen activator (tPA) and other agents ex vivo to influence fibrinolysis capacity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Viscoelastometric assessment of fibrinolysis
Description: Viscoelastometric assessment of whole blood fibrinolysis using supplemental tissue plasminogen activator (tPA) and other agents ex vivo to influence fibrinolysis capacity.
Study: NCT06681506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metronomic breathing, exercise rehabilitation, external counterpulsation, extracorporeal shock wave.
Description: Phase I rehabilitation(Metronomic breathing，exercise rehabilitation）,Phase II rehabilitation (exercise rehabilitation, external counterpulsation, extracorporeal shock) wave.)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bedside rehabilitation and breathing, balance, flexibility, movement rehabilitation
Description: Phase I rehabilitation (bedside rehabilitation, breathing rehabilitation), Phase II rehabilitation (breathing, balance, flexibility, movement)
Study: NCT05218668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil (WP-0512)
Description: Oral fasudil up to 180 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil (WP-0512)
Description: Oral fasudil up to 300 mg/day
Study: NCT05821426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eTrieve PE Kit
Description: Patients will be treated with the eTrieve PE Kit
Study: NCT06681792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Climate Change Workshops Based on Protection Motivation Theory
Description: The experimental group will take part in seven weekly workshops. One workshop will last 40 minutes.The workshop to be applied to the experimental group will take place every week and will last 40 minutes. The workshops, which are based on the Protection Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring environmentally friendly behaviour, recycling and the Green School Programme for sustainable environmental education.~The workshops include interactive applications such as students expressing their thoughts on the weekly themes, games, brainstorming, word cloud, planting trees, painting cloth bags, watching videos, making presentations on the themes. Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring enviro
Study: NCT06709950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular therapy
Description: Standard treatment
Study: NCT04894773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaginary Resistance Exercises
Description: In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Resisted Exercises
Description: In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
Study: NCT04661085

Intervention type: DIAGNOSTIC_TEST
Intervention: Broader Medical history and clinical tests
Description: Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
Study: NCT04607850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HPV
Description: Trial vaccine
Study: NCT05849259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Care Quality at Home
Description: Each of the two HBPC practices will identify at least two trained Dementia Care Quality at Home Champions who will be trained in the intervention comprised of 1) a standardized assessment tool to assess PLWD and caregiver needs; 2) seven modules created to optimize the well-being of the PLWD and their caregiver; and 3) regular team-based review of persons participating in the program to address care challenges and a team-based case conference approach to solve these challenges.
Study: NCT04607850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HPV
Description: Trial vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo vaccine
Study: NCT06431074

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 1
Description: Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calm Active Study Product 1.1 Usage
Description: Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
Study: NCT06221293

Intervention type: DIAGNOSTIC_TEST
Intervention: immunoenzyme analysis
Description: immunoenzyme analysis with EVOLIS system

Intervention type: DIAGNOSTIC_TEST
Intervention: immunoenzyme analysis
Description: immunoenzyme analysis with EVOLIS system
Study: NCT06379477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive surgeries
Description: after primary phacoemulsification surgery any resulting refractive error surprises will be corrected with different refractive surgery options

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive surgeries
Description: after primary phacoemulsification surgery any resulting refractive error surprises will be corrected with different refractive surgery options

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive surgeries
Description: after primary phacoemulsification surgery any resulting refractive error surprises will be corrected with different refractive surgery options
Study: NCT05941585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome injection30mg/m2
Description: Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)
Study: NCT05945524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow sampling
Description: Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
Study: NCT05941585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome injection30mg/m2
Description: Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HomoharringtonineD1-D7(2mg/m2/day)
Description: Homoharringtonine intravenous infusion on D1-D7,2mg/m2/day in a 4-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)
Description: Venetoclax d4-d12 (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)in a 4-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine(standard-dose:d1-d7100mg/m2/day)
Description: Cytarabine intravenous infusion on d1-d7 ,100mg/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine(standard-dose:d1-d7100mg/m2/day)
Description: Cytarabine intravenous infusion on d1-d7 ,100mg/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2)
Description: d1-d4100mg/m2/day, d5-d7 1g/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome injection24mg/m2
Description: Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (24mg/m2)
Study: NCT06174649

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reveal
Description: Reveal is a rapid AST method, which uses small molecule sensor technology to detect growth of bacterial populations by measuring volatile metabolites, and provides AST results in \~5 hours. Reveal™ is approved for clinical use in the European Union (EU) and Israel and approval is in process in India, and provides minimum inhibitory concentrations (MICs) for 28 antibiotics and 9 Gram negative species, that together account for \~90% of organisms causing Gram negative blood stream infections (BSI).
Study: NCT06007157

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypersodic/Hyposodic diet
Description: Participants will undergo a dietary intervention consisting of a week of high-sodium diet (4800 mg/day), followed by a week of low-sodium diet (1200 mg/day).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypersodic/Hyposodic diet
Description: Participants will undergo a dietary intervention consisting of a week of high-sodium diet (4800 mg/day), followed by a week of low-sodium diet (1200 mg/day).
Study: NCT06019494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte retrieval with low aspiration flow rate
Description: All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.42 ml/sec.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte retrieval with high aspiration flow rate
Description: High aspiration flow rate All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.62 ml/sec.
Study: NCT05885750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unprocessed
Description: Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mildly processed
Description: Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heavily refined
Description: Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
Study: NCT05805150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens (stenfilcon A)
Description: One week wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens (stenfilcon A)
Description: One week wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens (senofilcon A)
Description: One week wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens (senofilcon A)
Description: One week wear
Study: NCT05395312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online blended stepped-care mental well-being platform
Description: Participants in experimental group will be stratified according to their level of anxiety and/or depressive symptoms.~Level 2 (normal range)~* Topic-based personal growth articles, exercises, and chatbots~* Webinars and talks on varied mental health related topics~* Virtual support community~Level 3 (mild to moderate)~* Online self-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online skills-based workshops, questions-and-answers sessions, retreats~Level 4 (severe)~* Online coach-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online group therapy, 4-week group cognitive behavioural therapy or 8-week group mindfulness-based cognitive therapy
Study: NCT06349837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiotherapy
Description: LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.
Study: NCT04936594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: 1800 pulses of iTBS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: MagVenture MagPro x100 device. This will be used as the comparator.
Study: NCT05766501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily